Hospitals rely on scores of generic drugs given by injection. But these workhorses are often in short supply. Cheap prices have led to factory closures that leave the supply chain vulnerable.
Laura Bray couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.
The recent, abrupt shortage of critical cancer drugs is forcing doctors to ration essential medications. It highlights a broken business model in generic drugs.
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
Journalist Katherine Eban says most of the generic medicine being sold in the U.S. is manufactured overseas — sometimes under questionable quality control standards. Her new book is Bottle of Lies.
Civica Rx has plans to become an alternative source of generic drugs at reasonable prices for hospitals. The company's first medicines will be the antibiotics vancomycin and daptomycin.